LAUSR

Recently, the efficacy of probiotics in treatment of neurodegenerative disorders has been reported in animal or clinical studies. Therefore, we assessed the effects of Bacillus coagulans JA845 in counteracting the symptoms of D-galactose (D-gal)/AlCl3-induced mice model of Alzheimer's disease (AD) through behavioral test, histological assessment and biochemical analysis. Ten weeks of pre-treatment with B. coagulans JA845 prevented cognitive decline, attenuated hippocampal lesion and protected neuronal integrity, which demonstrated the neuroprotective features of B. coagulans JA845 in vivo. We also found that supplementation of B. coagulans JA845 alleviated amyloid-beta deposits and hyperphosphorylated tau in hippocampus of D-gal/AlCl3-induced AD model mice. Furthermore, B. coagulans JA845 administration attenuated oxidative stress and decreased serum concentration of inflammatory cytokines by regulating Nrf2/HO-1 and MyD88/TRAF6/NF-κB pathway. Our results first demonstrated that B. coagulans has the potential benefits for preventing cognitive decline and might be a novel therapeutic approach for the treatment of neurodegenerative diseases.